Patient demographics
Demographic characteristic . | Relapsed/refractory NHL . | First-line therapy . |
|---|---|---|
| No. patients | 995 | 76 |
| Sex | ||
| Male, no. (%) | 586 (59) | 41 (54) |
| Female, no. (%) | 409 (41) | 35 (46) |
| Median age, y (range) | 58 (21-88) | 49 (23-69) |
| Median time from diagnosis to protocol entry, mo (range) | 45 (2-334) | 8 (1-105) |
| Grade at protocol entry, no. (%) | ||
| Low grade | 766 (77) | 76 (100) |
| Transformed low grade | 218 (22) | 0 (0) |
| Intermediate/high grade | 11 (1) | 0 (0) |
| Ann Arbor stage III/IV at enrollment, no. (%) | 883/994 (89) | 76 (100) |
| Bone marrow involvement, no. (%) | 414/990 (42) | 48/75 (64) |
| Elevated LDH, no. (%) | 90/224 (40) | 23/75 (31) |
| Decreased platelets,* no. (%) | 245 (25) | 8 (11) |
| Decreased ANC,† no. (%) | 301 (30) | 16 (21) |
| Median number of prior therapies (range) | 3 (1-13) | 0 (0-0) |
| Patients with 4 or more prior therapies, no. (%) | 351 (35) | 0 (0) |
| Previously received rituximab, no. (%) | 470 (47) | 0 (0) |
| Previously received fludarabine, no. (%) | 103/230 (45) | 0 (0) |
| Previously received anthracycline or anthracenedione, no. (%) | 185/230 (80) | 0 (0) |
| Previously received alkylator, no. (%) | 227/230 (99) | 0 (0) |
| Previously received radiotherapy, no. (%) | 244 (25) | 0 (0) |
Demographic characteristic . | Relapsed/refractory NHL . | First-line therapy . |
|---|---|---|
| No. patients | 995 | 76 |
| Sex | ||
| Male, no. (%) | 586 (59) | 41 (54) |
| Female, no. (%) | 409 (41) | 35 (46) |
| Median age, y (range) | 58 (21-88) | 49 (23-69) |
| Median time from diagnosis to protocol entry, mo (range) | 45 (2-334) | 8 (1-105) |
| Grade at protocol entry, no. (%) | ||
| Low grade | 766 (77) | 76 (100) |
| Transformed low grade | 218 (22) | 0 (0) |
| Intermediate/high grade | 11 (1) | 0 (0) |
| Ann Arbor stage III/IV at enrollment, no. (%) | 883/994 (89) | 76 (100) |
| Bone marrow involvement, no. (%) | 414/990 (42) | 48/75 (64) |
| Elevated LDH, no. (%) | 90/224 (40) | 23/75 (31) |
| Decreased platelets,* no. (%) | 245 (25) | 8 (11) |
| Decreased ANC,† no. (%) | 301 (30) | 16 (21) |
| Median number of prior therapies (range) | 3 (1-13) | 0 (0-0) |
| Patients with 4 or more prior therapies, no. (%) | 351 (35) | 0 (0) |
| Previously received rituximab, no. (%) | 470 (47) | 0 (0) |
| Previously received fludarabine, no. (%) | 103/230 (45) | 0 (0) |
| Previously received anthracycline or anthracenedione, no. (%) | 185/230 (80) | 0 (0) |
| Previously received alkylator, no. (%) | 227/230 (99) | 0 (0) |
| Previously received radiotherapy, no. (%) | 244 (25) | 0 (0) |